Biogen cuts the price tag on its Alzheimer's drug in half

Biogen is slashing the price of Aduhelm, its Alzheimer’s treatment, in half. Months earlier, when it debuted, Biogen received criticism for its initial cost, which could reach $56,000 annually.

Video transcript

[MUSIC PLAYING]

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting